BSX Add to watchlist
$43.04 +0.41 (+0.97%)
After Hours: $43.04 +0.00 (+0.00%)
Last updated: Jul 15, 2026 23:06
52-Week Range
$43.04
$42.20 $43.04 $109.50

Fundamentals Overview

Boston Scientific Corporation is near the low of its 52-week range with attractive valuation, trading relatively flat today.

Valuation attractive

P/E 18.1 PEG 0.24 P/B 2.47 P/S 3.1

Intrinsic value (DCF)

+140.4% upside vs price

Profitability

Net margin 17.2%

Risk (Beta)

0.58 — lower vol

Earnings & growth

EPS $2.38 Rev -1.6% Profit +100.1% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 56% confidence Risk: Lower Volatility — Beta 0.58. Diversify and only invest what you can afford to lose.

Supporting (Buy):

DCF +140.4% upside vs price · Analyst grade: B+

Pressures (Sell):

Sentiment weakening (2 downgrades) · 3M vs S&P 500: -41.9% · 3M vs Healthcare sector: -38.9%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$63.97B
P/E (TTM)
18.11
EPS (TTM)
$2.38
Dividend Yield
N/A
52-Week Range
$42.20 - $109.50
Volume vs Avg
N/A
Beta
0.58

About

Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointest...
Sector: Healthcare
Headquarters: US
Employees: 59,000
IPO Date: May 1992
Beta: 0.58 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: B+. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 16, Equal Weight: 1, Outperform: 8, Overweight: 4, Peer Perform: 1.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $103.45; current price is $43.04. That’s a +140.4% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 18.11
DCF value (model) $103.45 (140.4% upside)
PEG (TTM) 0.24
P/B (TTM) 2.47
P/S (TTM) 3.1
P/FCF (TTM) 18.59
Liquidity & enterprise
Current Ratio (TTM) 1.9
Quick Ratio (TTM) 1.22
Cash Ratio (TTM) 0.33
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 17.24%
Gross margin (TTM) 70.41%
Operating margin (TTM) 20.12%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for BSX.

Analyst Sentiment at a Glance

B+ Sentiment Weakening
Buy 16Equal Weight 1Outperform 8Overweight 4Peer Perform 1
0 upgrades, 2 downgrades
Price Target Consensus
Current $43.04
Median $70.00
Consensus $78.10
Low consensus $55.00
High consensus $120.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Mizuho maintain Outperform Outperform 2026-07-15
RBC Capital maintain Outperform Outperform 2026-07-13
Needham maintain Buy Buy 2026-07-08
Evercore ISI Group maintain Outperform Outperform 2026-07-06
Stifel maintain Buy Buy 2026-06-25
Jefferies maintain Buy Buy 2026-06-24
BTIG maintain Buy Buy 2026-06-16
Truist Securities maintain Buy Buy 2026-06-04
BTIG maintain Buy Buy 2026-06-03
Canaccord Genuity maintain Buy Buy 2026-06-01
Wolfe Research downgrade Outperform Peer Perform 2026-05-29
Citigroup maintain Buy Buy 2026-05-28
Wells Fargo downgrade Overweight Equal Weight 2026-05-28
Barclays maintain Overweight Overweight 2026-05-28
Leerink Partners maintain Outperform Outperform 2026-05-28
Baird maintain Outperform Outperform 2026-05-19
Needham maintain Buy Buy 2026-05-18
B of A Securities maintain Buy Buy 2026-05-18
BTIG maintain Buy Buy 2026-05-18
Needham maintain Buy Buy 2026-04-23
Barclays maintain Overweight Overweight 2026-04-23
Evercore ISI Group maintain Outperform Outperform 2026-04-23
Truist Securities maintain Buy Buy 2026-04-23
Baird maintain Outperform Outperform 2026-04-23
Goldman Sachs maintain Buy Buy 2026-04-23
Canaccord Genuity maintain Buy Buy 2026-04-23
RBC Capital maintain Outperform Outperform 2026-04-23
Wells Fargo maintain Overweight Overweight 2026-04-23
Barclays maintain Overweight Overweight 2026-04-22
Jefferies maintain Buy Buy 2026-04-22